Amicus Therapeutics Presents New Data on Galafold and Pombiliti+ Opfolda at WORLDSymposium 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5d ago
0mins
Should l Buy FOLD?
Amicus Therapeutics announced the presentation of new data from clinical and real-world studies of Galafold in Fabry disease and Pombiliti+ Opfolda in late-onset Pompe disease. Data are being presented at the 22nd Annual WORLDSymposium 2026. "Amicus continues to advance the science and understanding of both Fabry and Pompe diseases, and we are proud to showcase new data for our medicines at this year's WORLDSymposium. These new data add to the growing body of evidence supporting the important role of Galafold and Pombiliti + Opfolda," said Jeff Castelli, PhD, Chief Development Officer, Amicus Therapeutics. "We are immensely grateful to the patients, their families, and investigators whose partnership makes scientific research and advances possible."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FOLD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FOLD
Wall Street analysts forecast FOLD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for FOLD is 14.25 USD with a low forecast of 11.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
3 Buy
7 Hold
0 Sell
Moderate Buy
Current: 14.280
Low
11.00
Averages
14.25
High
19.00
Current: 14.280
Low
11.00
Averages
14.25
High
19.00
About FOLD
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Halper Sadeh LLC Investigates Multiple Companies for Potential Violations
- Investigation Focus: Halper Sadeh LLC is investigating Janus Henderson Group plc, Amicus Therapeutics, Inc., and RAPT Therapeutics, Inc. for potential violations of federal securities laws related to their sales to Trian Fund Management, BioMarin Pharmaceutical, and GSK plc.
- Transaction Details: The cash sale price for Janus Henderson is $49.00 per share, Amicus is $14.50 per share, and RAPT is $58.00 per share, which may not adequately reflect the companies' true values, potentially harming shareholder interests.
- Shareholder Rights Protection: Halper Sadeh LLC may seek to secure increased consideration for shareholders, additional disclosures, and other relief measures to ensure the protection of shareholders' legal rights.
- Legal Service Commitment: The firm operates on a contingency fee basis, meaning shareholders are not responsible for out-of-pocket legal fees, and they encourage affected shareholders to consult for free regarding their legal rights and options.
See More
Warning Signs for Overbought Healthcare Stocks
- Overbought Signals: As of February 2, 2026, three stocks in the healthcare sector are showing overbought signals with RSI values exceeding 70, indicating potential short-term pullback risks that investors should be cautious about.
- Brookdale Senior Living: This company's stock is in an overbought state with an RSI of 80.4, reflecting strong price momentum but also suggesting possible price adjustment risks, prompting investors to monitor market developments closely.
- Amicus Therapeutics Acquisition: Amicus Therapeutics announced its acquisition by BioMarin, with its stock price surging approximately 139% over the past six months to $14.29, while its RSI of 80.4 indicates strong market interest but also warns of potential corrections.
- Mirum Pharmaceuticals Performance: Mirum Pharmaceuticals is also in an overbought condition, and investors should pay attention to its RSI and market performance to assess future investment risks and opportunities.
See More
BioMarin Pharmaceutical Set to Report 2025 Financial Results Soon
- Earnings Report Anticipation: BioMarin is expected to announce its Q4 and full-year 2025 results in the coming weeks, with last year's report released on the third Wednesday of February, prompting investors to mark February 18, 2026, on their calendars for potential updates.
- Voxzogo Sales Outlook: CFO Brian Mueller indicated that Voxzogo is projected to achieve its highest revenue level of the year in Q4, reflecting strong demand for rare disease drugs, which could drive overall performance growth.
- FDA Approval Progress: The FDA has set a PDUFA date of February 28, 2026, for BioMarin's Palynziq in treating adolescents with phenylketonuria, and approval could provide a new revenue stream, enhancing the company's competitive position.
- Market Competition Risks: Despite positive short-term factors, management expresses caution regarding Voxzogo's long-term outlook, acknowledging potential challenges from competitors that could impact market share and revenue expectations.
See More
BioMarin Expects Strong Sales for Voxzogo in Q4
- Voxzogo Sales Outlook: BioMarin anticipates that its rare disease drug Voxzogo will achieve its highest sales level in Q4 2024, as CFO Brian Mueller indicated during the Q3 earnings call, which is expected to drive revenue growth and bolster investor confidence.
- Guidance Adjustment: The company raised the lower end of its 2025 revenue guidance to $3.15 billion, reflecting optimistic expectations for Q4 performance, which may reduce the risk of negative surprises in earnings reports and further solidify market trust in the company.
- FDA Approval Catalyst: BioMarin expects to receive an FDA approval decision for Palynziq on February 28, 2026, which could provide new growth opportunities for the company, with potential EU approval also anticipated in the first half of the year.
- Competition Risks: Despite BioMarin's optimistic outlook for Voxzogo, management acknowledged potential competitive pressures that could impact market share in 2027, necessitating careful risk assessment by investors.
See More
Halper Sadeh Investigates Amicus Therapeutics Sale to BioMarin at $14.50 per Share
- Acquisition Investigation: Halper Sadeh LLC is investigating whether the sale of Amicus Therapeutics to BioMarin at $14.50 per share is fair, aiming to protect shareholder rights and ensure reasonable compensation.
- Legal Compliance: The investigation focuses on whether Amicus's board violated federal securities laws and fiduciary duties, particularly regarding the failure to secure the best possible deal and disclose critical information.
- Shareholder Rights Protection: Halper Sadeh may seek increased consideration and additional disclosures for Amicus shareholders, enabling them to adequately assess the value and implications of the merger.
- Legal Fee Arrangement: The law firm will handle the case on a contingency fee basis, meaning shareholders will not be responsible for upfront legal costs, thereby reducing their financial burden.
See More
Halper Sadeh Investigates Potential Violations by Penumbra, Amicus, DigitalBridge, and Flushing Financial
- Investigation of Violations: Halper Sadeh LLC is investigating Penumbra, Inc. (NYSE: PEN) regarding its sale to Boston Scientific Corporation for either 3.8721 shares of Boston Scientific stock or $374.00 in cash, potentially breaching fiduciary duties to shareholders.
- Amicus Transaction Review: Amicus Therapeutics, Inc. (NASDAQ: FOLD) is being sold to BioMarin Pharmaceutical Inc. for $14.50 per share, with Halper Sadeh LLC possibly seeking increased consideration and additional disclosures for shareholders.
- DigitalBridge Sale Concerns: DigitalBridge Group, Inc. (NYSE: DBRG) is selling to SoftBank Group Corp. for $16.00 per share in cash, prompting Halper Sadeh LLC to assess potential infringements on shareholder rights.
- Flushing Financial Investigation: Flushing Financial Corp. (NASDAQ: FFIC) is selling for 0.85 shares of OceanFirst stock per share, with Halper Sadeh LLC potentially advocating for greater shareholder rights and transparency in the transaction.
See More
Halper Sadeh LLC Investigates Multiple Companies for Potential Violations
- Investigation Focus: Halper Sadeh LLC is investigating Janus Henderson Group plc, Amicus Therapeutics, Inc., and RAPT Therapeutics, Inc. for potential violations of federal securities laws related to their sales to Trian Fund Management, BioMarin Pharmaceutical, and GSK plc.
- Transaction Details: The cash sale price for Janus Henderson is $49.00 per share, Amicus is $14.50 per share, and RAPT is $58.00 per share, which may not adequately reflect the companies' true values, potentially harming shareholder interests.
- Shareholder Rights Protection: Halper Sadeh LLC may seek to secure increased consideration for shareholders, additional disclosures, and other relief measures to ensure the protection of shareholders' legal rights.
- Legal Service Commitment: The firm operates on a contingency fee basis, meaning shareholders are not responsible for out-of-pocket legal fees, and they encourage affected shareholders to consult for free regarding their legal rights and options.
See More
Warning Signs for Overbought Healthcare Stocks
- Overbought Signals: As of February 2, 2026, three stocks in the healthcare sector are showing overbought signals with RSI values exceeding 70, indicating potential short-term pullback risks that investors should be cautious about.
- Brookdale Senior Living: This company's stock is in an overbought state with an RSI of 80.4, reflecting strong price momentum but also suggesting possible price adjustment risks, prompting investors to monitor market developments closely.
- Amicus Therapeutics Acquisition: Amicus Therapeutics announced its acquisition by BioMarin, with its stock price surging approximately 139% over the past six months to $14.29, while its RSI of 80.4 indicates strong market interest but also warns of potential corrections.
- Mirum Pharmaceuticals Performance: Mirum Pharmaceuticals is also in an overbought condition, and investors should pay attention to its RSI and market performance to assess future investment risks and opportunities.
See More
BioMarin Pharmaceutical Set to Report 2025 Financial Results Soon
- Earnings Report Anticipation: BioMarin is expected to announce its Q4 and full-year 2025 results in the coming weeks, with last year's report released on the third Wednesday of February, prompting investors to mark February 18, 2026, on their calendars for potential updates.
- Voxzogo Sales Outlook: CFO Brian Mueller indicated that Voxzogo is projected to achieve its highest revenue level of the year in Q4, reflecting strong demand for rare disease drugs, which could drive overall performance growth.
- FDA Approval Progress: The FDA has set a PDUFA date of February 28, 2026, for BioMarin's Palynziq in treating adolescents with phenylketonuria, and approval could provide a new revenue stream, enhancing the company's competitive position.
- Market Competition Risks: Despite positive short-term factors, management expresses caution regarding Voxzogo's long-term outlook, acknowledging potential challenges from competitors that could impact market share and revenue expectations.
See More
BioMarin Expects Strong Sales for Voxzogo in Q4
- Voxzogo Sales Outlook: BioMarin anticipates that its rare disease drug Voxzogo will achieve its highest sales level in Q4 2024, as CFO Brian Mueller indicated during the Q3 earnings call, which is expected to drive revenue growth and bolster investor confidence.
- Guidance Adjustment: The company raised the lower end of its 2025 revenue guidance to $3.15 billion, reflecting optimistic expectations for Q4 performance, which may reduce the risk of negative surprises in earnings reports and further solidify market trust in the company.
- FDA Approval Catalyst: BioMarin expects to receive an FDA approval decision for Palynziq on February 28, 2026, which could provide new growth opportunities for the company, with potential EU approval also anticipated in the first half of the year.
- Competition Risks: Despite BioMarin's optimistic outlook for Voxzogo, management acknowledged potential competitive pressures that could impact market share in 2027, necessitating careful risk assessment by investors.
See More
Halper Sadeh Investigates Amicus Therapeutics Sale to BioMarin at $14.50 per Share
- Acquisition Investigation: Halper Sadeh LLC is investigating whether the sale of Amicus Therapeutics to BioMarin at $14.50 per share is fair, aiming to protect shareholder rights and ensure reasonable compensation.
- Legal Compliance: The investigation focuses on whether Amicus's board violated federal securities laws and fiduciary duties, particularly regarding the failure to secure the best possible deal and disclose critical information.
- Shareholder Rights Protection: Halper Sadeh may seek increased consideration and additional disclosures for Amicus shareholders, enabling them to adequately assess the value and implications of the merger.
- Legal Fee Arrangement: The law firm will handle the case on a contingency fee basis, meaning shareholders will not be responsible for upfront legal costs, thereby reducing their financial burden.
See More
Halper Sadeh Investigates Potential Violations by Penumbra, Amicus, DigitalBridge, and Flushing Financial
- Investigation of Violations: Halper Sadeh LLC is investigating Penumbra, Inc. (NYSE: PEN) regarding its sale to Boston Scientific Corporation for either 3.8721 shares of Boston Scientific stock or $374.00 in cash, potentially breaching fiduciary duties to shareholders.
- Amicus Transaction Review: Amicus Therapeutics, Inc. (NASDAQ: FOLD) is being sold to BioMarin Pharmaceutical Inc. for $14.50 per share, with Halper Sadeh LLC possibly seeking increased consideration and additional disclosures for shareholders.
- DigitalBridge Sale Concerns: DigitalBridge Group, Inc. (NYSE: DBRG) is selling to SoftBank Group Corp. for $16.00 per share in cash, prompting Halper Sadeh LLC to assess potential infringements on shareholder rights.
- Flushing Financial Investigation: Flushing Financial Corp. (NASDAQ: FFIC) is selling for 0.85 shares of OceanFirst stock per share, with Halper Sadeh LLC potentially advocating for greater shareholder rights and transparency in the transaction.
See More
